All In Biotech

NDA 021708 · Somerset

Emsam

Selegiline · Transdermal

Last checked: Nov 20, 2026Latest source record: Feb 27, 2006 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Feb 27, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

34

3 Phase 3, 0 recruiting

FAERS reports

2,999

1,411 serious, 174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • EMSAM · SELEGILINE 9MG · SYSTEM, TRANSDERMAL · Prescription
  • EMSAM · SELEGILINE 12MG · SYSTEM, TRANSDERMAL · Prescription
  • EMSAM · SELEGILINE 6MG · SYSTEM, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Selegiline" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective329
  • insomnia189
  • application site erythema183
  • hallucination171
  • dizziness170
  • fall147
  • dyskinesia140
  • drug interaction135
  • anxiety128
  • depression128
  • application site rash127
  • tremor121

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
200635
2007311
200827
200943
201034
2011203
2012182
2013145
201451
2015199
2016194
2017224
2018174
2019195
2020193
2021165
2022129
2023147
2024112
2025132
2026100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Emsam (Selegiline)

2024 spending

$12.5M

Beneficiaries

866

5,355 claims

Per beneficiary

$14,487

$71.43 per unit

View as table
YearSpending
2020$11,786,120
2021$12,367,030
2022$11,918,838
2023$12,397,890
2024$12,546,115

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 290 on PubMed

Sponsor: Somerset

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.